Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Jeff P. Sharman*, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutre, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence CymbalistaJennifer A. Woyach, Emmanuelle Ferrant, William G. Wierda, Veerendra Munugalavadla, Ting Yu, Min Hui Wang, John C. Byrd

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1171-1175
Number of pages5
JournalLeukemia
Volume36
Issue number4
DOIs
StatePublished - Apr 2022
Externally publishedYes

Funding

FundersFunder number
Acerta Pharma
Acerta, Pharmacyclics, and Zencor
Seattle Genetics, Takeda
US Oncology
Eli Lilly and Company
AstraZeneca
Genentech
Novartis
Roche
Gilead Sciences
Teva Pharmaceutical Industries
Ohio State University
Janssen Pharmaceuticals
Hairy Cell Leukemia Foundation
CancerCare Manitoba Foundation
Leukemia and Lymphoma Society of Canada
Seattle Genetics
TG Therapeutics
Canadian Institutes of Health Research

    Cite this